Company Description
Tiziana Life Sciences Ltd. engages in the research and development of biotechnological and pharmaceutical products. It develops transformative therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer related to the liver. Its clinical pipeline includes Foralumab, Anti IL...
Tiziana Life Sciences Ltd. engages in the research and development of biotechnological and pharmaceutical products. It develops transformative therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer related to the liver. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.
Valuation
Price to Book Ratio
2.38
Enterprise Value to EBITDA
-3.38
Efficiency
Liquidity
Current Ratio
6.45
Quick Ratio
6.45
Cash Ratio
5.59
Profitability
Return on Assets
-39.16
Return on Equity
-45.14
Return on Total Capital
-54.35
Capital Structure
Total Debt to Total Assets
2.78
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Gabriele Marco Antonio Cerrone | 48 | 1998 | Executive Chairman |
Ms. Keeren Shah | 45 | 2020 | Finance Director |
Dr. Vaseem A. Palejwala | - | 2017 | Director-Clinical Operations |
Dr. Kunwar Shailubhai | 64 | 2008 | CEO, Executive Director & Chief Scientific Officer |
Insider Actions
10/05/2021 |
Gabriele Marco Antonio Cerrone |
60,000 | Acquisition at $0.52 per share. | 31,050 |
10/04/2021 |
Gabriele Marco Antonio Cerrone |
60,000 | Acquisition at $0.55 per share. | 33,000 |
10/04/2021 |
Gabriele Marco Antonio Cerrone |
60,000 | Acquisition at $0.5 per share. | 30,000 |
10/01/2021 |
Gabriele Marco Antonio Cerrone |
37,500 | Acquisition at $0.49 per share. | 18,300 |
09/27/2021 |
Gabriele Marco Antonio Cerrone |
100,000 | Acquisition at $0.52 per share. | 52,000 |
05/20/2021 |
Gabriele Marco Antonio Cerrone |
10,000 | Acquisition at $0.71 per share. | 7,100 |
12/09/2020 |
Gabriele Marco Antonio Cerrone |
38,000 | Acquisition at $0.78 per share. | 29,640 |
11/18/2020 |
Gabriele Marco Antonio Cerrone |
45,000 | Acquisition at $0.84 per share. | 37,800 |
02/03/2020 |
Gabriele Marco Antonio Cerrone |
5,000 | Acquisition at $2.37 per share. | 11,850 |
01/13/2020 |
Gabriele Marco Antonio Cerrone |
28,500 | Acquisition at $0.43 per share. | 12,255 |
12/31/2019 |
Gabriele Marco Antonio Cerrone |
12,500 | Acquisition at $2.79 per share. | 34,875 |
MarketWatch News on TLSA
-
Tesla Hit a New High. No, It Was TLSA. Confused?
- Barron's Online
-
Tesla's stock drops 3.3% premarket, after soaring 9.0% Wednesday to record high
- Tomi Kilgore
Other News on TLSA
-
Tiziana appoints former Endo exec as chief medical officer
- Seeking Alpha
-
Tiziana Life Sciences CEO Kunwar Shailubhai resigns
- Seeking Alpha
-
General Motors Is Catching Up To Tesla
- Seeking Alpha
-
Nasdaq sends non-compliance notice to Tiziana Life Sciences
- Seeking Alpha
-
Talon Metals And The Defense Production Act
- Seeking Alpha
-
KNDI, LILM and ADN among mid- day movers
- Seeking Alpha
-
Stock Split Watch: Is Amazon Next?
- Motley Fool
-
Warning: TLSA is at high risk of performing badly
- Seeking Alpha
-
TLSA is at high risk of performing badly
- Seeking Alpha
-
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
- InvestorPlace.com
-
GSAT, GDP and ASMB among mid-day movers
- Seeking Alpha
-
DQ, BTBT and GOTU among pre market gainers
- Seeking Alpha
-
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
- InvestorPlace.com
- Loading more headlines...